[1]
|
Boström, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al. (2012) A PGC1-α-Dependent Myokine That Drives Brown-Fat-Like Development of White Fat and Thermogenesis. Nature, 481, 463-468.
https://doi.org/10.1038/nature10777
|
[2]
|
Zhang, D., Tan, X., Tang, N., Huang, F., Chen, Z. and Shi, G. (2020) Review of Research on the Role of Irisin in Tumors. OncoTargets and Therapy, 13, 4423-4430. https://doi.org/10.2147/OTT.S245178
|
[3]
|
Timmons, J., Baar, K., Davidsen, P. and Atherton, P.J. (2012) Is Irisin a Human Exercise Gene? Nature, 488, E9-E10.
https://doi.org/10.1038/nature11364
|
[4]
|
Maak, S., Norheim, F., Drevon C. and Erickson, H.P. (2021) Progress and Challenges in the Biology of FNDC5 and Irisin. Endocrine Reviews, 42, 436-456. https://doi.org/10.1210/endrev/bnab003
|
[5]
|
Aydin, S., Kuloglu, T., Aydin, S., Kalayci, M., Yilmaz, M., Cakmak, T., et al. (2014) A Comprehensive Immunohistochemical Examination of the Distribution of the Fat-Burning Protein Irisin in Biological Tissues. Peptides, 61, 130-136. https://doi.org/10.1016/j.peptides.2014.09.014
|
[6]
|
Huh, J., Panagiotou, G., Mougios, V., Brinkoetter, M., Vamvini, M.T., Schneider, B.E., et al. (2012) FNDC5 and Irisin in Humans: I. Predictors of Circulating Concentrations in Serum and Plasma and II. mRNA Expression and Circulating Concentrations in Response to Weight Loss and Exercise. Metabolism: Clinical and Experimental, 61, 1725-1738.
https://doi.org/10.1016/j.metabol.2012.09.002
|
[7]
|
Sumsuzzman, D., Jin, Y., Choi, J., Yu, J.H., Lee, T.H. and Hong, Y. (2019) Pathophysiological Role of Endogenous Irisin against Tumorigenesis and Metastasis: Is It a Potential Biomarker and Therapeutic? Tumor Biology, 41, Article ID: 1010428319892790. https://doi.org/10.1177/1010428319892790
|
[8]
|
Gao, C., Sun, X., Lu, L., Liu, F. and Yuan, J. (2019) Prevalence of Gestational Diabetes Mellitus in Mainland China: A Systematic Review and Meta-Analysis. Journal of Diabetes Investigation, 10, 154-162.
https://doi.org/10.1111/jdi.12854
|
[9]
|
Cui, L., Qiao, T., Xu, F., Li, Z., Chen, T., Su, H., et al. (2020) Circulating Irisin Levels of Prenatal and Postnatal Patients with Gestational Diabetes Mellitus: A Systematic Review and Meta-analysis. Cytokine, 126, Article ID: 154924.
https://doi.org/10.1016/j.cyto.2019.154924
|
[10]
|
Kuzmicki, M., Telejko, B., Lipinska, D., Pliszka, J., Szamatowicz, M., Wilk, J., et al. (2014) Serum Irisin Concentration in Women with Gestational Diabetes. Gynecological Endocrinology, 30, 636-369.
https://doi.org/10.3109/09513590.2014.920006
|
[11]
|
吴棣, 刘子宸, 高妍, 王文丽. 孕早期鸢尾素水平与孕妇糖脂代谢和妊娠期糖尿病风险的分析[J]. 皖南医学院学报, 2021, 40(4): 369-371.
|
[12]
|
Yuksel, M., Oncul, M., Tuten, A., Imamoglu, M., Acikgoz, A.S., Kucur, M., et al. (2014) Maternal Serum and Fetal Cord Blood Irisin Levels in Gestational Diabetes Mellitus. Diabetes Research and Clinical Practice, 104, 171-175.
https://doi.org/10.1016/j.diabres.2013.12.025
|
[13]
|
Wang, P., Ma, H., Hou, X., Song, L.L., Song, X.L. and Zhang, J.F. (2018) Reduced Plasma Level of Irisin in first Trimester as a Risk Factor for the Development of Gestational Diabetes Mellitus. Diabetes Research and Clinical Practice, 142, 130-138. https://doi.org/10.1016/j.diabres.2018.05.038
|
[14]
|
Du, X.L., Jiang, W.X. and Lv, Z.T. (2016) Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research, 48, 644-652.
https://doi.org/10.1055/s-0042-108730
|
[15]
|
Erol, O., Erkal, N., Ellidağ, H., İsenlik, B.S., Aydın, Ö., Derbent, A.U., et al. (2016) Irisin as an Early Marker for Predicting Gestational Diabetes Mellitus: A Prospective Study. The Journal of Maternal-Fetal & Neonatal Medicine, 29, 3590-3595. https://doi.org/10.3109/14767058.2016.1142967
|
[16]
|
叶丽燕, 范徐妃, 郑秀娟. 低分子肝素预防子痫前期的效果[J]. 中国妇幼保健, 2021, 36(24): 5610-5612.
https://doi.org/10.19829/j.zgfybj.issn.1001-4411.2021.24.001
|
[17]
|
Garcés, M., Peralta, J., Ruiz-Linares, C., Lozano, A.R., Poveda, N.E., Torres-Sierra, A.L., et al. (2014) Irisin Levels during Pregnancy and Changes Associated with the Development of Preeclampsia. The Journal of Clinical Endocrinology and Metabolism, 99, 2113-2119. https://doi.org/10.1210/jc.2013-4127
|
[18]
|
谢莉莉, 彭凯伟, 方成志. 新生儿脐带血鸢尾素水平与出生体重及宫内生长受限的关系[J]. 医学研究杂志, 2017, 46(12): 95-9. https://doi.org/10.11969/j.issn.1673-548X.2017.12.024
|
[19]
|
Zhang, L., Xie, Q., Tang, C. and Zhang, A.H. (2017) Expressions of Irisin and Urotensin II and Their Relationships with Blood Pressure in Patients with Preeclampsia. Clinical and Experimental Hypertension, 39, 460-467.
https://doi.org/10.1080/10641963.2016.1273945
|
[20]
|
邓文娟, 王静, 宁改君, 任卫东, 左丽娟. 妊娠期甲减患者孕晚期鸢尾素水平与机体代谢指标及母婴妊娠结局的相关性分析[J]. 现代预防医学, 2021, 48(6): 1145-1148.
|
[21]
|
夏显, 漆洪波. 美国母胎医学会《妊娠期肝内胆汁淤积症指南(2020版)》解读[J]. 实用妇产科杂志, 2021, 37(8): 587-590.
|
[22]
|
陈嘉卿, 马俊如, 石秉知, 李琴. 妊娠期肝内胆汁淤积症患者血清、脐静脉血鸢尾素水平变化及相关性研究[J]. 现代妇产科进展, 2019, 28(3): 202-205. https://doi.org/10.13283/j.cnki.xdfckjz.2019.03.009
|
[23]
|
Chen, J., Li, Q. and Ma J. (2021) Maternal Serum, Placental, and Umbilical Venous Blood Irisin Levels in Intrahepatic Cholestasis of Pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine, 34, 2403-2410.
https://doi.org/10.1080/14767058.2019.1667322
|
[24]
|
Kirbas, A., Daglar, K., Timur, H., Biberoglu, E., Inal, H.A., Kara, O., et al. (2016) Maternal Circulating Levels of Irisin in Intrahepatic Cholestasis of Pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine, 29, 3483-3487.
https://doi.org/10.3109/14767058.2015.1132694
|
[25]
|
沈林萍, 李艳, 仝玉丽. 妊娠期肝内胆汁淤积症孕妇外周血、脐静脉血中鸢尾素变化及相关性分析[J]. 中国医学创新, 2021, 18(10): 18-23. https://doi.org/10.3969/j.issn.1674-4985.2021.10.005
|
[26]
|
Adamska, A., Karczewska-Kupczewska, M., Lebkowska, A., Milewski, R., Górska, M., Otziomek, E., et al. (2016) Serum Irisin and Its Regulation by Hyperinsulinemia in Women with Polycystic Ovary Syndrome. Endocrine Journal, 63, 1107-1112. https://doi.org/10.1507/endocrj.EJ16-0249
|
[27]
|
Gao, S., Cheng, Y., Zhao, L., Chen, Y. and Liu, Y. (2016) The Relationships of Irisin with Bone Mineral Density and Body Composition in PCOS patients. Diabetes/Metabolism Research and Reviews, 32, 421-428.
https://doi.org/10.1002/dmrr.2767
|
[28]
|
Wang, C., Zhang, X., Sun, Y., Hou, X.G. and Chen, L. (2018) Higher Circulating Irisin Levels in Patients with Polycystic Ovary Syndrome: A Meta-Analysis. Gynecological Endocrinology, 34, 290-293.
https://doi.org/10.1080/09513590.2017.1393065
|
[29]
|
Bostancı, M., Akdemir, N., Cinemre, B., Cevrioglu, A.S., Özden, S. and Ünal, O. (2015) Serum Irisin Levels in Patients with Polycystic Ovary Syndrome. European Review for Medical and Pharmacological Sciences, 19, 4462-4468.
|
[30]
|
Cai, X., Qiu, S., Li, L., Zügel, M., Steinacker, J.M. and Schumann, U. (2018) Circulating Irisin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis. Reproductive Biomedicine Online, 36, 172-180.
https://doi.org/10.1016/j.rbmo.2017.10.114
|
[31]
|
Li, M., Yang, M, Zhou, X., Fang, X., Hu, W., Zhu, W., et al. (2015) Elevated Circulating Levels of Irisin and the Effect of Metformin Treatment in Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism, 100, 1485-1493. https://doi.org/10.1210/jc.2014-2544
|
[32]
|
Bousmpoula, A., Benidis, E., Demeridou, S., Kapeta-Kourkouli, R., Chasiakou, A., Chasiakou, S., et al. (2019) Serum and Follicular Fluid Irisin Levels in Women with Polycystic Ovaries Undergoing Ovarian Stimulation: Correlation with Insulin Resistance and lipoprotein Lipid Profiles. Gynecological Endocrinology, 35, 803-806.
https://doi.org/10.1080/09513590.2019.1594761
|
[33]
|
Bacopoulou, F., Athanasopoulos, N., Efthymiou, V., Mantzou, A., Aravantinos, L., Vlahopoulos, S., et al. (2018) Serum Irisin Concentrations in Lean Adolescents with Polycystic Ovary Syndrome. Clinical Endocrinology, 88, 585-591.
https://doi.org/10.1111/cen.13555
|
[34]
|
Chang, C., Huang, S., Soong, Y., Cheng, P.J., Wang, C.J. and Liang, I.T. (2014) Circulating Irisin and Glucose-Dependent Insulinotropic Peptide Are Associated with the Development of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism, 99, E2539-E2548. https://doi.org/10.1210/jc.2014-1180
|
[35]
|
Farhan, F. and Hussien, S. (2019) Irisin as a Novel Marker for Insulin Resistance in Iraqi Women with Polycystic Ovary Syndrome before and after Metformin Therapy. Journal of Obstetrics and Gynaecology of India, 69, 194-200.
https://doi.org/10.1007/s13224-018-1176-7
|
[36]
|
Foda, A., Foda, E. and El-Said, Z. (2019) Serum Irisin Levels in Polycystic Ovary Syndrome after Ovarian Drilling. Diabetes & Metabolic Syndrome, 13, 1463-1468. https://doi.org/10.1016/j.dsx.2019.02.019
|
[37]
|
Masaeli, A., Nayeri, H. and Mirzaee, M. (2019) Effect of Metformin Treatment on Insulin Resistance Markers, and Circulating Irisin in Women with Polycystic Ovarian Syndrome (PCOS). Hormone and Metabolic Research, 51, 575-579. https://doi.org/10.1055/a-0896-1130
|
[38]
|
Abali, R., Temel Yuksel, I., Yuksel, M., Bulut, B., Imamoglu, M., Emirdar, V., et al. (2016) Implications of Circulating Irisin and Fabp4 Levels in Patients with Polycystic Ovary Syndrome. Journal of Obstetrics and Gynaecology, 36, 897-901. https://doi.org/10.3109/01443615.2016.1174200
|
[39]
|
Wang, W., Guo, Y., Zhang, X. and Zheng, J. (2018) Abnormal Irisin Level in Serum and Endometrium Is Associated with Metabolic Dysfunction in Polycystic Ovary Syndrome Patients. Clinical Endocrinology, 89, 474-480.
https://doi.org/10.1111/cen.13805
|
[40]
|
Pukajło, K., Łaczmański, Ł., Kolackov, K., Kuliczkowska-Płaksej, J., Bolanowski, M., Milewicz, A., et al. (2015) Irisin Plasma Concentration in PCOS and Healthy Subjects Is Related to Body Fat Content and Android Fat Distribution. Gynecological Endocrinology, 31, 907-911. https://doi.org/10.3109/09513590.2015.1065482
|
[41]
|
Li, H., Xu, X., Wang, X., Liao, X., Li, L., Yang, G., et al. (2016) Free Androgen Index and Irisin in Polycystic Ovary Syndrome. Journal of Endocrinological Investigation, 39, 549-556. https://doi.org/10.1007/s40618-015-0403-7
|
[42]
|
Kuloglu, T., Celik, O., Aydin, S., Hanifi Ozercan, I., Acet, M., Aydin, Y., et al. (2016) Irisin Immunostaining Characteristics of Breast and Ovarian Cancer Cells. Cellular and Molecular Biology, 62, 40-44.
|
[43]
|
程亚玉, 张萍, 谭雪莹. 宫颈癌组织Irisin表达临床意义研究[J]. 中华肿瘤防治杂志, 2017, 24(21): 1523-1529.
https://doi.org/10.16073/j.cnki.cjcpt.2017.21.007
|
[44]
|
朱英雪, 张萍. Irisin促进上皮性卵巢癌细胞生长增殖[J]. 实用妇科内分泌电子杂志, 2019, 6(16): 130+161.
https://doi.org/10.16484/j.cnki.issn2095-8803.2019.16.092
|
[45]
|
Moon, H. and Mantzoros, C. (2014) Regulation of Cell Proliferation and Malignant Potential by Irisin in Endometrial, Colon, Thyroid and Esophageal Cancer Cell Lines. Metabolism: Clinical and Experimental, 63, 188-193.
https://doi.org/10.1016/j.metabol.2013.10.005
|